publication date: Dec. 3, 2013
20131203 - Dec. 3, 2013
ISSUE 41 – NOV. 1, 2013PDF


Rosen Moves to City of Hope

Steven Rosen is leaving his job as director of Northwestern University Robert H. Lurie Cancer Center to become the center director, provost, and chief scientific officer at City of Hope National Medical Center.

The move is interesting in part because, after 25 years in the top job at Northwestern, Rosen is the second longest-serving director of a cancer center in the U.S. (Rosen’s friend Max Wicha, who became director of the University of Michigan Cancer Center 27 years ago, is the first.)


Conversation with The Cancer Letter: Steven Rosen

Robert Stone, president and incoming CEO of City of Hope, described the evolution of the novel leadership structure at his institution.

While most directors of cancer centers have to fulfill a multitude of very different roles, City of Hope has redistributed these roles, creating the role of provost and chief scientific officer to shape and direct the scientific and educational activities at the institution.

The role encompasses all units of City of Hope: the Comprehensive Cancer Center, the Beckman Research Institute of City of Hope, a National Medical Center, a Medical Foundation, a graduate school for biological sciences, and nationwide philanthropy.

photoQuality of Care: ASCO Publishes “Top Five” Ways to Improve Cancer Care

The American Society of Clinical Oncology published its second list of five opportunities to improve the quality and value of cancer care in the Journal of Clinical Oncology.

photoCost of Care: Medicare Patients Charged More In Outpatient Care Settings

Patients receiving chemotherapy in hospital outpatient departments face up to 47 percent higher costs compared to patients treated in physician community cancer clinics, according to a report prepared by The Moran Company and released by The US Oncology Network and the Community Oncology Alliance.

photoIn Brief

  • Larry Kun Named Clinical Director at St. Jude

  • Paula Rieger, CEO of the Oncology Nursing Society, announces plans to retire

  • FDA Approves Gazyva in CLL, The Agency’s First Approval of a Breakthrough Therapy

  • FDA Requests Manufacturer Suspend Sales and Marketing of Iclusig

Copyright (c) 2020 The Cancer Letter Inc.